New data from the BENEFIT study demonstrate that belatacept improves long-term allograft and patient survival after kidney transplantation, despite higher rates of biopsy-proven acute rejection than with ciclosporin. The noninferiority design of BENEFIT represents a feasible strategy to further the development of innovator drugs to reduce late graft loss.
机构:
Univ Calif San Francisco, Kidney Transplant Serv, San Francisco, CA 94143 USAUniv Calif San Francisco, Kidney Transplant Serv, San Francisco, CA 94143 USA
Wojciechowski, David
Vincenti, Flavio
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif San Francisco, Kidney Transplant Serv, San Francisco, CA 94143 USAUniv Calif San Francisco, Kidney Transplant Serv, San Francisco, CA 94143 USA
机构:
Nephrologie und Hypertensiologie, Universitätsklinikum Erlangen, Friedrich Alexander Universität Erlangen-Nürnberg, Ulmenweg 18, ErlangenNephrologie und Hypertensiologie, Universitätsklinikum Erlangen, Friedrich Alexander Universität Erlangen-Nürnberg, Ulmenweg 18, Erlangen